Meeting
2014 Breast Cancer Symposium
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.
Authors
Peter Kaufman
Norris Cotton Cancer Center and Dartmouth-Hitchcock Medical Center, Lebanon, NH
Peter Kaufman , Chris Twelves , Javier Cortes , Linda T. Vahdat , Martin Olivo , Yi He , Ahmad Awada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT00337103 and NCT00388726
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 137)
DOI
10.1200/jco.2014.32.26_suppl.137
Abstract #
137
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.
First Author: Chris Twelves
Poster
2014 Breast Cancer Symposium
Peripheral neuropathy (PN) in patients (pts) with metastatic breast cancer treated with eribulin: Resolution and association with efficacy.
First Author: Peter Kaufman
Poster
2022 ASCO Annual Meeting
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
First Author: Se Hyun Kim
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao